1. Home
  2. LAAC vs TOVX Comparison

LAAC vs TOVX Comparison

Compare LAAC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LAAC
  • TOVX
  • Stock Information
  • Founded
  • LAAC 2007
  • TOVX 2001
  • Country
  • LAAC Canada
  • TOVX United States
  • Employees
  • LAAC N/A
  • TOVX N/A
  • Industry
  • LAAC
  • TOVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LAAC
  • TOVX Health Care
  • Exchange
  • LAAC Nasdaq
  • TOVX Nasdaq
  • Market Cap
  • LAAC 542.4M
  • TOVX 3.5M
  • IPO Year
  • LAAC N/A
  • TOVX 2006
  • Fundamental
  • Price
  • LAAC $2.74
  • TOVX $1.14
  • Analyst Decision
  • LAAC Hold
  • TOVX Strong Buy
  • Analyst Count
  • LAAC 3
  • TOVX 1
  • Target Price
  • LAAC $5.58
  • TOVX $6.00
  • AVG Volume (30 Days)
  • LAAC 1.3M
  • TOVX 96.3K
  • Earning Date
  • LAAC 11-05-2024
  • TOVX 11-12-2024
  • Dividend Yield
  • LAAC N/A
  • TOVX N/A
  • EPS Growth
  • LAAC 3133.17
  • TOVX N/A
  • EPS
  • LAAC 7.78
  • TOVX N/A
  • Revenue
  • LAAC N/A
  • TOVX N/A
  • Revenue This Year
  • LAAC N/A
  • TOVX N/A
  • Revenue Next Year
  • LAAC $208.49
  • TOVX N/A
  • P/E Ratio
  • LAAC $0.35
  • TOVX N/A
  • Revenue Growth
  • LAAC N/A
  • TOVX N/A
  • 52 Week Low
  • LAAC $2.07
  • TOVX $1.14
  • 52 Week High
  • LAAC $6.69
  • TOVX $17.00
  • Technical
  • Relative Strength Index (RSI)
  • LAAC 36.55
  • TOVX 36.15
  • Support Level
  • LAAC $2.69
  • TOVX $1.23
  • Resistance Level
  • LAAC $3.21
  • TOVX $1.21
  • Average True Range (ATR)
  • LAAC 0.17
  • TOVX 0.07
  • MACD
  • LAAC -0.04
  • TOVX 0.01
  • Stochastic Oscillator
  • LAAC 12.86
  • TOVX 0.00

About LAAC Lithium Americas (Argentina) Corp.

Lithium Argentina is a pure-play lithium producer. The company owns two neighboring lithium brine resources in northwest Argentina: Cauchari-Olaroz and Pastos Grandes. Cauchari-Olaroz entered production in 2023, while Pastos Grandes is still in development. Lithium Argentina plans for both resources to be fully integrated with onside downstream processing capabilities and will sell into the lithium chemical market.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: